SCHEMBL3889926

SCHEMBL3889926

CCCN(CCOc1ccc(N)cn1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
CHEK2 O96017 1/20 0.38
CYP2D6 P10635 3/20 0.38
CYP1A2 P05177 3/20 0.38
SCN1A P35498 2/20 0.38
SCN2A Q99250 2/20 0.38
SCN3A Q9NY46 2/20 0.38
LMNA P02545 2/20 0.36
CYP3A4 P08684 2/20 0.36
CHRM2 P08172 2/20 0.36
KCNH2 Q12809 2/20 0.36
HTR1A P08908 1/20 0.36
GAA P10253 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TSHR P16473 2/20 0.36
MAOA P21397 2/20 0.36
HTR3A P46098 2/20 0.36
HRH3 Q9Y5N1 2/20 0.36
KEAP1 Q14145 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027194 0.84 KDM4E (0.36) MAPTCHEK2CYP2D6CYP1A2SCN1A
SCHEMBL16973093 0.83 CHEK2 (0.43) MAPTCHEK2KEAP1PAICSPHLPP2
SCHEMBL3887047 0.77 MEN1 (0.38) CYP2D6CYP1A2SCN1ASCN2ASCN3A
SCHEMBL4900712 0.77 KDM4E (0.36) MAPTCHEK2CYP2D6CYP1A2SCN1A
SCHEMBL6764285 0.77 LMNA (0.37) MAPTCHEK2CYP2D6CYP1A2SCN1A
SCHEMBL16973165 0.76 CHEK2 (0.42) MAPTCHEK2KEAP1PAICSPHLPP2
SCHEMBL31237102 0.76 KDM4E (0.50) MAPTCYP2D6CYP3A4GAATSHR
SCHEMBL16322624 0.76 KDM4E (0.50) MAPTCYP2D6CYP3A4GAATSHR
SCHEMBL529529 0.75 HTR7 (0.46) CHEK2KEAP1PHLPP2CHRNA4POLB
SCHEMBL30615515 0.75 HTR7 (0.46) CHEK2KEAP1PHLPP2CHRNA4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed